Hypomagnesemia is a highly prevalent clinical condition affecting a large number of hospitalized patients. A decrease in systemic magnesium concentration may lead to impaired function of both neurologic and cardiovascular systems. The kidney has a pivotal role in magnesium handling by adjusting the urinary excretion of this ion in order to maintain systemic concentrations within a narrow range. As such, the cause of hypomagnesemia can be related to increments in the renal excretion of this cation. Many hypomagnesemic disorders also have characteristic changes in the renal reabsorptive capacity for other electrolytes, leading to symptoms that sometimes obscure the clinical presentation. For instance, changes in serum calcium concentration or its urinary excretion can aid in determining the underlying cause. Moreover, hypokalemia due to renal potassium losses often is associated with hypomagnesemia. Genetic defects in pathways controlling renal electrolyte transport impose the hypomagnesemic condition by facilitating renal losses. The discovery of the causative genes has greatly increased our understanding of how magnesium is transported by the kidney. Such knowledge is integral for the continued improvement of patient care with respect to bettering therapies and diagnosis. Am J Kidney Dis. 62(2):377-383.
INTRODUCTION
Hypomagnesemia is a clinical condition that arises frequently, with a prevalence of ϳ10% in hospitalized patients and up to 65% in intensive care unit patients. 1 Hypomagnesemia may be due to isolated losses, but commonly is associated with other electrolyte disorders (eg, hypokalemia or hypocalcemia) that may obscure the clinical presentation. By studying the causative genes in electrolyte disorders with disturbed magnesium handling and the pathophysiologic consequences of their absence, it is possible to increase our understanding of how magnesium homeostasis is maintained. Given the frequency of hypomagnesemia, it is essential for clinicians to understand its pathogenesis. The symptoms of complex electrolyte disorders involving hypomagnesemia are represented by the present teaching case. It is our intent to emphasize how magnesium balance is maintained, how it can be perturbed by genetic abnormalities in electrolyte transport pathways, and the steps that should be taken by clinicians to reach a diagnosis.
CASE REPORT

Clinical History and Initial Laboratory Data
A 16-year-old girl was admitted to the clinic because of persistent vomiting and abdominal pain. History did not show any prior illness. On repeated questioning, she mentioned carpopedal spasms during infections. At examination, there was diffuse abdominal pain with rebound, and bowel sounds were minimal. Elevated leukocyte count (18.1 ϫ10 3 /L) supported a presumed diagnosis of appendicitis, and an appendectomy was performed. The appendix appeared to be grossly and histologically normal. Postoperatively, vomiting continued and bowel sounds remained absent. Determination of serum electrolyte levels indicated severe hypokalemia (Table 1) . Intravenous supplementation with potassium chloride was started, which resulted in complete recovery within 24 hours, suggesting that the abdominal symptoms were due to hypokalemia-induced ileus.
Additional Investigations
An electrolyte panel drawn postoperatively showed abnormalities in serum and urinary electrolyte levels (Table 1) .
Diagnosis
The combination of lower serum potassium and magnesium levels with increased renal loss, accompanied by low urinary calcium excretion, pointed to the diagnosis of Gitelman syndrome.
A homozygous nonsynonymous mutation (a threonine to arginine change at amino acid 649 [T649R]) subsequently was discovered in the thiazide-sensitive sodium/chloride cotransporter (NCC), which is encoded by the SLC12A3 gene. The family history of our patient has been described previously in a Dutch-language medical journal.
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Clinical Follow-up
The patient was treated with oral potassium chloride (2 g 4 times daily; 4 mEq of potassium per kilogram of body weight every 24 hours) and magnesium oxide (500 mg thrice daily; 18 mg of magnesium ion per kilogram of body weight every 24 hours), which normalized serum electrolyte levels (Table 1) .
DISCUSSION
Disorders of hypomagnesemia are characteristic of a subset of conditions that may result from disturbances in renal electrolyte transport. The extracellular concentration of magnesium is maintained at 1.4-2.2 mEq/L. 3 Hypomagnesemia is diagnosed when serum magnesium concentration is decreased to Ͻ1.4 mEq/L. Failure to maintain serum magnesium levels within the normal range is not inconsequential. Hypomagnesemia results in a whole range of symptoms, including neuromuscular irritability such as tetany, positive Chvostek and Trousseau signs, seizures, and cardiac arrhythmias. 4, 5 A list of frequently reported symptoms of hypomagnesemia can be found in Box 1. In our index patient, carpopedal spasms were observed during infections, which could be attributed to hypomagnesemia. It has been reported that symptomatic hypomagnesemia is particularly apparent during common infections of childhood in patients with hereditary hypomagnesemic conditions. ] blood )) ϫ [Cr] urine ϫ 100. To adjust for the amount of magnesium filtered by the kidney, serum magnesium concentration is multiplied by 0.7. 1 In the presence of hypomagnesemia, decreased FE Mg (Ͻ2%) suggests that the kidney is responding appropriately to a decreased serum magnesium ion concentration. 1, 7 Thus, normal urinary excretion of magnesium (in children, 0.16-0.30 mEq per kilogram of body weight in a 24-hour period) in the presence of hypomagnesemia may indicate a renal defect.
Hypomagnesemia frequently is observed in conjunction with other electrolyte imbalances, including hypokalemia and hypocalcemia, as well as metabolic acidbase disturbances. The exact reason for the secondary hypocalcemia observed during severe magnesium depletion is unclear, but may be due to blunted release of parathyroid hormone or desensitization to parathyroid hormone in bone. 8, 9 Hypokalemia is an oftenencountered condition associated with hypomagnesemia and may be present in a large number of patients with hypomagnesemia.
10,11 Hypokalemia can be refractory to potassium administration in certain cases. During these conditions, the addition of magnesium can aid in correcting potassium losses. 11 Interestingly, disorders leading to isolated hypokalemia do not promote magnesium wasting, whereas hypomagnesmia can, but does not necessarily, produce secondary decreases in serum potassium levels. One proposed explanation for this phenomenon involves ROMK (the renal outer medullary K ϩ channel), which is a key player in potassium secretion from the collecting system. 11, 12 Potassium permeation through ROMK channels can be blocked by physiologic levels of magnesium. 12 In conditions of hypomagnesemia, this blockage probably is lifted. 11, 12 Hypomagnesemia most often is the result of acquired disorders. Causes due to renal magnesium wasting are listed in Box 2. However, hypomagnesemia also can • Positive Trousseau sign (muscle spasm in hand and forearm after occlusion of the brachial artery)
• Arrhythmias result from genetic defects in renal transport proteins (Table 2) . Understanding how each nephron segment contributes to ion reabsorption and which electrolyte transport processes likely are disturbed aids in pinpointing the cause of hypomagnesemia. Classic genetic defects that lead to hypomagnesemia due to renal wasting localize to the thick ascending limb and the distal convoluted tubule (DCT) in the nephron (Table 2 ; Fig 1) . These disorders can be differentiated by the appearance of calciuria as a hallmark feature of the underlying disease. The lumen-positive transepithelial voltage difference is critical for driving paracellular reabsorption of magnesium and calcium across the thick ascending limb. 31 The electric gradient is dependent on adequate function of thick ascending limb transporters. The preferential paracellular permeability to cations through the claudin 16-19 complex seems necessary to permit calcium and magnesium reabsorption in the segment. 32, 33 Hypercalciuria is a recurrent feature in antenatal Bartter syndrome, and nephrocalcinosis commonly can be observed. 34 In classic Bartter syndrome, patients typically lack nephrocalcinosis and may present with hyper-or normocalciuria. 31, 35 Nevertheless, patients with Bartter syndrome only develop hypomagnesemia to a varying degree. 31, 35 Prolonged use of loop diuretics can cause significant hypomagnesemia in some patients. Genetic disorders due to defects in the claudin 16-19 complex lead to familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC). 24, 25 These patients are hypomagnesemic and present with massive calcium wasting and nephrocalcinosis, but disturbances in sodium chloride handling have not been described in humans. Abbreviations: EAST, epilepsy, ataxia, sensorineural deafness, and tubulopathy; FHHNC, familial hypomagnesemia with hypercalciuria and nephrocalcinosis; HSH, hypomagnesemia with secondary hypocalcemia; SeSAME, seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance. Gene and protein abbreviations are defined in text.
a Synthesized as a large precursor that subsequently is cleaved to liberate the EGF peptide.
frequently are observed in the former, whereas a milder ocular phenoype is present only infrequently in the latter. 24, 25 Magnesium reabsorption occurs through active transcellular transport in the DCT. 36 The negative membrane potential of the DCT cell likely is a major determinant of magnesium uptake across the apical membrane. 31 The transient receptor potential melastin 6 channel (TRPM6) is a divalent cation-permeable channel that allows influx of magnesium in this segment. 37 Genetic defects in TRPM6 lead to the autosomal recessive disorder hypomagnesemia with secondary hypocalcemia (HSH). 27, 28 This disorder is primarily absorptive and patients often present early in life with severe hypomagnesemia and secondary hypocalcemia. 31 Individuals with HSH also present with a renal magnesium leak. 28 Given the importance of TRPM6 in magnesium transport, it is not surprising that disruption of pathways regulating TRPM6 cause renal wasting of the cation and concomitant hypomagnesemia. 21, [27] [28] [29] [30] Genetic defects promoting hypomagnesemia due to perturbed DCT transport frequently are associated with hypocalciuria, as well as hypokalemia. Most often encountered clinically is the autosomal recessive disorder Gitelman syndrome. The underlying genetic defects are mutations in the SLC12A3 gene encoding NCC. 26 A subset of patients with Gitelman syndrome also has been described who have mutations in the CLCNKB gene, which encodes the chloride channel Kb (CLC-Kb). 38 Gitelman syndrome is a salt-losing disorder with the characteristic features of hypokalemic metabolic alkalosis, hypomagnesemia, and hypocalciuria. 35 Similar clinical presentations can be observed in patients undergoing treatment with thiazide diuretics. 31 Hypocalciuria in Gitelman syndrome can be explained by the observation that thiazide-induced extracellular volume depletion increases proximal tubular sodium reabsorption and subsequent water removal. This leads to an increased luminal calcium concentration in the proximal tubule, augmenting the transtubular driving force for calcium and thereby increased reabsorption of the cation through the paracellular shunt. 39 In addition, a poorly described distal mechanism may be involved. 40 Hypokalemia in Gitelman syndrome is thought to be associated predominantly with compensatory sodium transport in the collecting duct system that drives potassium secretion. Hypomagnesemia in Gitelman syndrome presumably is caused by a reduced abundance of TRPM6; however, the responsible mechanism remains incompletely understood. 39, 41, 42 Animals with abolished NCC function, either genetically or pharmacologically, display significant atrophy of the initial part of the DCT, potentially explaining the downregulation of TRPM6. 39, 41, 42 However, when thiazide dosages are decreased to prevent atrophy of the DCT, TRPM6 expression remains lowered. transport in the DCT is an active process and is strongly dependent on the electrical potential difference across the apical membrane. TRPM6 is likely the key entry pathway for Mg 2ϩ in the segment. Abbreviations: CaSR, Ca 2ϩ -sensing receptor; CLC-Kb, chloride channel Kb; EGF, epidermal growth factor; HNF1B, hepatocyte nuclear factor 1B; Kv1.1, shaker-related voltage-gated K ϩ channel; Kir4.1, inwardly-rectifying K ϩ channel; NCC, thiazide-sensitive NaCl cotransporter; NKCC2, Na ϩ /K ϩ /2Cl Ϫ cotransporter; ROMK, renal outer medullary K ϩ channel; TRPM6, transient receptor potential melastin 6 channel.
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A rare genetic defect has been described that is suspected to impair sodium chloride transport in the DCT and thereby result in a Gitelman syndrome-like phenotype. Mutations in the KCNJ10 gene, which encodes an inwardly rectifying potassium channel (Kir4.1), leads to EAST (epilepsy, ataxia, sensorineurol deafness, and tubulopathy) and SeSAME (seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance). The tubulopathy presents as hypokalemic metabolic alkalosis with hypomagnesemia and hypocalciuria akin to Gitelman syndrome.
22,23 Kir4.1 is situated in the basolateral membrane of the DCT, as well as in other epithelial cells within the distal part of the nephron. It has been suggested that the channel functions in potassium recycling across the basolateral membrane in order to maintain the sizeable sodium/potassium-transporting adenosine triphosphatase (Na ϩ /K ϩ -ATPase) activity in the segment. 43 Absence of the channel therefore would limit the transepithelial driving force for sodium and thereby limit sodium chloride transport through the NCC. In addition, decreased Na ϩ /K ϩ -ATPase activity is likely to depolarize the cell and thus limit uptake of magnesium from the luminal fluid through TRPM6.
Mutations in the Na ϩ /K ϩ -ATPase ␥ subunit (encoded by the FXYD2 gene) lead to a rare condition of isolated dominant hypomagnesemia with hypocalciuria. However, hypokalemia is not part of the clinical presentation. 18, 44 The involvement of this mutation in promoting hypomagnesemia has been linked to a decrease in outward basolateral sodium transport in the DCT and secondary decreases in the intracellular voltage, diminishing the inward electric driving force for transit of magnesium through TRPM6. Hepatocyte nuclear factor 1B (HNF1B) has been shown to regulate the transcription of the FXYD2 protein. 19 Consistent with this, patients with mutations in the HNF1B gene can present with hypomagnesemia and hypocalciuria. 19 A recent report detailing the clinical presentation of 27 adult patients with HNF1B defects identified hypokalemia due to renal wasting in about half the tested patients. 20 Interestingly, most hypokalemic patients were hypomagnesemic, whereas only about half the patients with hypomagnesemia presented with hypokalemia. Moreover, oral supplementation with potassium or magnesium was ineffective in increasing the serum concentrations of either cation. 20 The reason for potassium wasting in this condition is unclear, but may be related to the hypokalemic effect of hypomagnesemia, altered transcriptional control of HNF1B genes (thus also affecting the FXYD2 gene), or a combination of both.
Two rare autosomal disorders have been reported that cause isolated renal hypomagnesemia (ie, without associated changes in serum or urinary calcium and potassium levels). Mutations in the pro-epidermal growth factor (EGF) gene cause isolated renal hypomagnesemia. 29 Because EGF is a potent stimulator of TRPM6, defects in the processing of this hormone cause dysregulation of TRPM6 and thus renal magnesium wasting. Moreover, EGF receptor inhibitors, which often are used as anticancer drugs, promote hypomagnesemia due to renal wasting. 29, 45 Mutations in the shaker-related voltage-gated potassium channel (Kv1.1), found in the apical DCT membrane and important in maintaining membrane voltage, lead to hypomagnesemia, presumably by decreasing the inward driving force for transit of magnesium through TRPM6. 30 Recently, it was found that mutations in the CNNM2 gene, which encodes a basolateral protein located in the DCT, is the cause of isolated dominant hypomagnesemia. 21 This finding indicates that CNNM2 is critical for the basolateral excretion of magnesium. Patients affected by this rare mutation present with low to normal excretion of calcium.
The diagnostic approach to a patient with hypomagnesemia is summarized briefly next. The origin of hypomagnesemia might be inferred from patient history, current medication, or the presence of pathologic states commonly associated with hypomagnesemia. Possible causes of extrarenal origin should be consulted. 4, 13 Renal magnesium wasting is indicated when the kidney fails to decrease FE Mg to Ͻ2% in a hypomagnesemic individual with a normal glomerular filtration rate. 1 Importantly, elevations in FE Mg may be seen with creatinine clearances Ͻ30 mL/ min. 46 The 24-hour urinary magnesium excretion can be in the normal range in mildly depleted hypomagnesemic patients. Most commonly acquired causes of renal hypomagnesemia are listed in Box 2. Genetic syndromes also may be considered based on patient history and presentation. Genetic disorders can be differentiated to a certain degree by accompanying changes in serum and urinary calcium excretion and sometimes by the occurrence of other electrolyte disturbances as hallmark features of the underlying disease. Thus, measurement of calcium to creatinine
Box 3. Key Teaching Points
• Hypomagnesemia as an isolated electrolyte abnormality is relatively uncommon, but more often associated with additional electrolyte disturbances
• Signs and symptoms of hypomagnesemia often do not appear until serum magnesium concentration decreases to Ͻ0.8-1 mEq/L • Hypomagnesemia is related most frequently to renal wasting of the ion
• Tubular defects in magnesium transport can predispose to hypomagnesemia ratio, as well as electrolyte panels, may aid in pinpointing the exact genetic defect. Table 2 lists the various genetic disorders of hypomagnesemia due to renal wasting and the studies in which they were identified, and Box 3 lists key teaching points.
